Cardiology Continuing Medical Education

Be part of the knowledge.™

Cardiology

179

LikeLikedUnlike

Episodes 1-15 of 28

- Robert J. Chilton, DO
  Peer
- John R. Nelson, MD, FACC, FNLA, FASNC
  Peer
1
CME/CE
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
1.00 credits
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
1
CME/CE
From Guidelines to Practice: Key Updates From 2021 HFSA
From Guidelines to Practice: Key Updates From 2021 HFSA
0.25 credits
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
- Gregg C. Fonarow, MD
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
2
CME/CE
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
1.50 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
5
CME/CE
A New Normal? COVID-19 and HF in Clinical Trials
A New Normal? COVID-19 and HF in Clinical Trials
0.25 credits
- George L. Bakris, MD
  Peer
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
  Peer
- Bertram Pit, MD
  Peer
8
CME/CE
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
0.25 credits
- Robert J. Mentz, MD, FHFSA, FACC, FAHA
  Peer
- Peter van der Meer, MD, PhD
  Peer
3
CME/CE
A Clinical Guide to the Role of Iron in HF Pathophysiology
A Clinical Guide to the Role of Iron in HF Pathophysiology
0.25 credits
- George L. Bakris, MD
  Peer
- Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
  Peer
- Robert Toto, MD
  Peer
3
CME/CE
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal
0.25 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
3
CME/CE
Optimizing RAASi Therapy in Patients with Hyperkalemia: The Role of Potassium Binders
Optimizing RAASi Therapy in Patients with Hyperkalemia: The Role of Potassium Binders
0.25 credits
- Joseph Saseen, PharmD, BCPS, BCACP, CLS
  Peer
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
  Peer
2
CME/CE
Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?
Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?
0.25 credits
- John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
  Peer
3
CME/CE
The ABCs of CTD-PAH: (A)lgorithms, Team-(B)ased Approach, and (C)ombination Therapy
The ABCs of CTD-PAH: (A)lgorithms, Team-(B)ased Approach, and (C)ombination Therapy
1.25 credits
- Erin D. Michos, MD, MHS, FACC, FAHA, FASE
  Peer
- Leslie Cho, MD
  Peer
6
CME/CE
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
0.25 credits
- George L. Bakris, MD
  Peer
- Biff F. Palmer, MD
  Peer
3
CME/CE
RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option
RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option
0.25 credits
- Hector O. Chapa, MD
  Peer
- Marc S. Sabatine, MD, MPH
  Peer
0
CME/CE
Optimizing LDL-C Management in the Post-MI Patient
Optimizing LDL-C Management in the Post-MI Patient
0.50 credits
- Paul W. Armstrong, MD
  Peer
- Justin Ezekowitz, MD, MBBCh, MSc
  Peer
4
CME/CE
Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness
Emerging Data on New Therapy Combinations for HFrEF: Raising Clinician Awareness
0.25 credits
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
4
CME/CE
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinicians
Potassium Binders Facilitate Continued RAASi Therapy: Helpful Tips for Clinicians
0.25 credits

Segment Chapters

Playlist:

Recommended